Reduced-intensity allogeneic HCT for chronic granulomatous disease can lead to two-year survival rates exceeding 95%, according to the results of a prospective multi-center trial. Median age of the 56 patients enrolled in the study was 12.7 years (range 0-40), and 42 patients (75%) had high-risk features. Graft sources were HLA-matched related donors (n=21) and HLA-matched unrelated donors (n=35). At median follow-up of 21 months, the two-year probability of survival and event-free survival was 96% and 91%, respectively.
Güngör T, et al. Lancet
Choose a Topic
- All Topics
- Patient Eligibility
- AML
- Unrelated Donor HCT
- Post-Transplant
- CIBMTR Publications
- GVHD
- ALL
- Lymphomas and CLL
- Preparative Regimens
- Pediatric HCT
- Older Patient HCT
- MDS
- Non-Malignant Disorders
- BMT CTN Publications
- Cord Blood
- Multiple Myeloma
- Sickle Cell Disease
- HLA Matching
- ASH 2015
- ASH 2017
- ASH 2016
- ASH 2020
- CML
- ASH 2018
- Neuroblastoma
Reduced-Intensity HCT for Chronic Granulomatous Disease
Feb 2014